MedTrace Logo

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

NCT06453902 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-21

No results posted yet for this study

Summary

A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment

Conditions

  • Chronic Myeloid Leukemia
  • Accelerated Phase CML

Interventions

DRUG

TGRX-678

All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Shenzhen Second People's Hospital

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • Tongji Medical College,Huazhong University of Science &Techonlogy

    collaborator UNKNOWN

  • Shenzhen TargetRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Qian Jiang, MD · Peking University People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2026-06-30
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06453902 on ClinicalTrials.gov